Ward Howell International (WHI), a global executive search firm, has acquired Curran Partners, a 28-year-old retained search firm headquartered in Stamford, Connecticut. Curran Partners’ operations and staff will be integrated into Ward Howell.
WHI is a rapidly growing, global executive search firm that last year recruited senior leaders in 97 countries across 27 international offices. For almost 70 years Ward Howell has been helping clients create a unique and sustainable talent advantage by recruiting excellent leaders. Unlike many of its major competitors, the company focuses on executive search as its core competency, avoiding the distraction of ancillary services.
Curran Partners, Inc. was founded in 1989 and became the U.S. member of the international network, ECI Group, in 2003. The firm serves clients in a variety of sectors, with particular focus on life sciences. Many of its clients are growth-stage biotech and pharma companies in various stages of drug development and commercial launch. Several are now firmly established as well-known, successful biotech/pharma organizations.
Michael Curran, Founder and Managing Partner, said “We are very pleased to join forces with Ward Howell and contribute to the continued growth of this highly-regarded brand. We look forward to building high-impact practice groups in several sectors, including life sciences. Having explored a number of prospective partners, Ward Howell was the clear choice. We share a commitment to excellence in executive recruiting and client service. Like us, WHI is keenly aware of the critical importance of recruiting only the strongest talent to provide clients with a competitive edge in the pursuit of their goals. We look forward to leveraging our shared ideals and combined resources to our clients’ advantage”.
Asad Haider, President Americas and Member of the Global Board, Ward Howell International, sees the acquisition of Curran Partners as an important step in further building WHI business in North America. He said, “The Curran Partners team significantly enhances our organizational capabilities and adds both breadth and depth to our key executive contacts in a range of sectors. The firm’s long record of building biotech firms from early stage development through commercial launch is a major addition to our life sciences platform. We now are strongly positioned in all sectors of life sciences, including large pharma, branded and generic medicines, across North America”.
SOURCE: Curran Partners